CTX112
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Lymphoma
Conditions
B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma
Trial Timeline
Mar 10, 2023 → Feb 1, 2030
NCT ID
NCT05643742About CTX112
CTX112 is a phase 1/2 stage product being developed by CRISPR Therapeutics for B-cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05643742. Target conditions include B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy.
What happened to similar drugs?
3 of 20 similar drugs in B-cell Lymphoma were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
9
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06925542 | Phase 1 | Recruiting |
| NCT05643742 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in B-cell Lymphoma